By: Flaka Ismaili    May 12, 2021

Welcome to Seeking Alpha’s Stocks to Watch – a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Podcasts, Stitcher and Spotify (click the highlighted links).

Heck, even the drivers themselves might start thinking of a different side hustle. Thus, for the folks that absolutely must travel, renting a car once they arrive at their destination should be more appealing. Well, the latest fallout sees UAL drop well below this rising support, which places it on this list of stocks to watch carefully. The German biotech innovator told Business Insider that it is already at work on the development of an adapted vaccine to combat the omicron variant.

Travel Stocks to Watch: Avis Budget Group (CAR)

Its offerings save people and companies time and money and should prove increasingly popular. Its services are enabling patients to virtually “visit” their healthcare providers. There’s much to like at any time about this more efficient mode of obtaining healthcare, but telahealth has been invaluable during the pandemic. Once many people experience the convenience of telehealth, it seems a good bet that they’ll be unlikely to go back to in-person healthcare visits unless necessary.

What’s worrisome for all involved is that over 3,200 people are onboard the affected ship, according to Louisiana Department of Health officials. Per News 18, anyone who tests positive during the disembarking process will either go directly home or self-isolate, with accommodations provided by the cruise ship operator. Since older folks tend to have more comorbidities, a highly infectious disease could spell problems, even if Crypto trader omicron is less potent. No pharmaceutical company has received as much positive press for its vaccine innovations as Pfizer. Earlier this month, CEO Albert Bourla was recommended by one InvestorPlace contributor for CEO of the year. New oral antivirals “could open up a broader population to Covid-19 treatments in a true outpatient setting,” wrote Goldman Sachs Group Inc. analyst Chris Shibutani in an Oct. 1 research note.

Coronavirus Stock To Watch: Medical Leader Baxter Falls From Buy Point In Today’s Market Sell-Off

Instead, I bought stock in companies that I liked or listened to advice from friends, who were always new to investing in the stock market. Some companies, however, are experiencing increased demand for some or all of their products and services because of the crisis. But that alone isn’t enough of a good reason to invest in these companies, at least not for the long run. Investors focused on the long term should favor the stocks of companies that seemed poised to get a sustainable boost from the pandemic, or at least have other catalysts for growth.

Pfizer and Moderna have predicted the virus will follow that of the flu, peaking seasonally — and spurring people to go for annual vaccinations. And the companies’ investments in their coronavirus programs show they believe this is a market that could generate revenue growth over the long term. The big biotech is now thinking about evaluating its antiviral drug remdesivir, which targets Ebola virus and Marburg virus, as a potential coronavirus treatment. Reuters reported last week that Gilead is in discussions with researchers in China and the U.S. about the potential for remdesivir to be used in treating the coronavirus. The sharp stock market sell-off caused by the coronavirus crisis has clearly changed the atmosphere on Wall Street.

Nasdaq

Evercore ISI referred to the two segments as “highlights” for the quarter. The Pleasanton, Calif.-based company sports a 40% pretax annual profit margin and a 24% return on equity from the fiscal year ended last January. For those numbers and several other metrics, VEEV stock merits passing grades in IBD Stock Checkup. The stock also earns a 98 Composite Rating, meaning it’s outpacing 98% of all stocks in terms of the most important stock-picking traits. In October, Veeva said it is increasing number of companies are adopting Veeva Vault CDMS to manage their clinical data. Investors have a lot to digest after panic over the economic impact of the coronavirus outbreak sent the market tumbling to its worst weekly loss since 2008 and the 10-year Treasury yield to a record low.

• And wild stock market swings have investors questioning how to handle stocks on the IBD Breakout Stocks Index, such as Netflix (NFLX), ZTO Express (ZTO), and New Oriental Education & Technology (EDU).
• As a side note, with how valuable used cars are, fewer miles could mean much more of a premium than ever before.
• Earlier this Summer, InvestorPlace analyst Louis Navellier called it a better buy among vaccine stocks than Pfizer.

Many folks are watching more TV and movies since they’re now home more often than usual. Moreover, movie theaters across the country and in many other countries are shut, which is another key factor driving demand for streamed content. Quidel stock is about 6% off its 52-week high after hitting a new high on April 17.

This would be a boon to Domino’s and other companies focused on food delivery. On Monday, the stock nudged above the entry before closing below it. Such indecisive action on the breakout day can signal the stock is not ready to continue its advance. Be on the lookout for a stronger move in heavy volume to indicate the stock is bypassing the resistance. Baxter stock is trading just under a 95.10 buy point in a cup base after Tuesday’s sharp losses, according to MarketSmith chart analysis. Staar Surgical is still forming a new base cup with a 42.83 buy point.

Vaccine Stocks to Watch: Novavax (NVAX)

This underscores the importance of doing your own research on any investment of interest. For a stock, consider how likely the company is to be able to remain competitive over the next decade. On a year-to-date basis, LUV is almost down 2% below breakeven, which is frustrating.

Enterprise software, online learning and internet retail are a few highlights, along with consumer staples and protective gear makers. Biotech, pharma and test-kit makers have rallied amid the rush for a coronavirus treatment or vaccine. The Covid-19 pandemic has paralyzed daily life for most and brought the global economy to a near standstill. But it has also yielded many new candidates for investors’ watchlists. The cloud play also made IBD’s latest list of new buys by the best mutual funds.

Therefore, Norwegian represents one of the stocks to watch, if only as an additional piece of evidence regarding omicron. Of course, the poster-child label could have happened to any cruise ship operator. To be sure, none of the https://investmentsanalysis.info/ major publicly owned companies in this space have fared well since the start of the crisis. In Carnival’s case, shares showed much promise following the April 2020 doldrums, when they were trading hands in the single digits.

• Mammen added that the company has already begun work on a new vaccine for exactly that purpose and will “rapidly progress into clinical trails” if it is deemed necessary.
• Some of these companies are working on COVID treatments and vaccines while others see a huge demand of their products and services during lockdowns caused by COVID-19 outbreaks and other pandemics.
• First, you have the countless number of employees that represent the broader air travel sector, many of whom lost their jobs during the initial wave of Covid-19.
• Biotech, pharma and test-kit makers have rallied amid the rush for a coronavirus treatment or vaccine.

Edwards Lifesciences is moving up the right side of a choppy cup base. For now, the buy point is 247.74, but be on the lookout for a potential handle to offer a more risk-optimal entry. One of the biggest biotechs in the world, Gilead Sciences (GILD -1.97%), is well-known for its drugs that treat the hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Gilead continues to make billions of dollars each year from its HCV and HIV franchises. “While overall life sciences clearly had an outsized benefit from Covid diagnostics, we would be curious to hear commentary around academic lab openings,” Evercore ISI said in a report. Strength from the specialty diagnostics unit “bodes well for the third quarter.”

Moderna

“Vaccines remain the primary prevention measure and largest market opportunity,” Morgan Stanley analyst Matthew Harrison wrote in a note dated Oct. 5.

Flaka Ismaili

More Posts